TP Therapeutics is presently conducting a Phase 1/2 clinical trial with our Investigational Drug, TPX-0005. This study is currently enrolling patients in the US and South Korea. More information about this study is available from www.clinicaltrials.gov. Patients and healthcare providers may also contact the TP Therapeutics Clinical Team about clinical trials in oncology at (858) 276-0005, or by email at firstname.lastname@example.org.
TPX-0005 was designed to target the oncogenic fusion genes of NTRK family, ROS1, and ALK that are present in certain cancers. With the advances in precision medicine, it is now possible for healthcare providers to test the abnormal genes in tumors and select a specific treatment based on the test results. The tyrosine kinase inhibitors targeting TRK family (TRKA, TRKB, and TRKC), ROS1, and ALK fusion protein have demonstrated great effectiveness in shrinking tumor or control the tumor growth in clinic. Nevertheless, there have been more and more cases of drug resistance after certain period of treatment. TP Therapeutics’ drug, TPX-0005, was created not only targeting the primary tumors with NTRK, ROS1 or ALK abnormal gene, but also the resistant tumors developed from tyrosine kinase inhibitor treatment. Therefore, TPX-0005 could be suitable for treating cancer patients with abnormal gene of NTRK, ROS1 or ALK including with resistance mutations. The suitable cancers may include:
Non-Small Cell Lung Cancer (NSCLC), Colorectal adenocarcinoma, Mammary Analogue of Secretory Carcinoma (MASC) of the salivary gland, Squamous cell head and neck cancer, Spitzoid melanoma, Gastrontestinal Stromal Tumor (GIST), Cholangiocarcinoma, Soft tissue sarcoma, Inflammatory Myofibroblastic Tumor (IMT), Soft tissue fibrosarcoma (pediatric), Soft tissue fibrosarcoma (pediatric), Soft tissue schwannoma (pediatric), Soft tissue hemangioma (pediatric), Soft tissue solitary fibrous tumor (pediatric), Infantile (congenital) fibrosarcoma, Glioblastoma Multiforme (GBM), Low grade glioma, Pediatric non-brainstem high grade glioma, Papillary thyroid, and Secretory breast carcinoma, Pigmented spindle cell nevus/Spitz nevus, Bladder cancer, Breast cancer, Rectal adenocarcinoma, Renal carcinoma, Renal medullary carcinoma, Thyroid cancer (anaplastic) and Thyroid cancer (medullary).
TPX-0005 could be used for treating resistant patients developed from the treatment(s) of:
TRK inhibitors: larotrectinib, entrectinib, LOXO-195 and others;
ROS1 inhibitors: crizotinib, lorlatinib, entrectinib, ceritinib, and others;
ALK inhibitors: crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, ensartinib, entrectinib, and others.